Pronota N.V. Patent applications |
Patent application number | Title | Published |
20140113308 | MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS - The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 04-24-2014 |
20130150282 | LTBP2 AS A BIOMARKER FOR EVALUATING THE RISK OF DEATH IN A DISEASED SUBJECT - The application discloses methods for treating a subject presenting with one or more signs of an inflammatory condition, or methods for evaluating the risk of death within a year for a subject presenting with one or more signs of an inflammatory condition, based on measuring the quantity of LTBP2 in a sample from the subject; and kits and devices for measuring LTBP2 and/or performing said methods. | 06-13-2013 |
20130129750 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 05-23-2013 |
20130116151 | BIOMARKER FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses a new tool for predicting, diagnosing and prognosing hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders; and kits and devices for measuring said biomarker and/or performing said methods. | 05-09-2013 |
20130045889 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 02-21-2013 |
20130040881 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria. | 02-14-2013 |
20120237962 | MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS - The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 09-20-2012 |
20120220493 | BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF - The application discloses MCAM as a new biomarker for acute heart failure; methods for predicting, diagnosing, prognosticating and/or monitoring acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 08-30-2012 |
20120142559 | BIOMARKERS AND PARAMETERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and/or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices. | 06-07-2012 |
20120034240 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 02-09-2012 |
20110275536 | BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF ACUTE HEART FAILURE AND USES THEREOF - The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 11-10-2011 |
20110256169 | NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE - The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis. | 10-20-2011 |
20110251094 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 10-13-2011 |
20110237513 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 09-29-2011 |
20110059858 | NEW BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF SEPSIS AND USES THEREOF - The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression level of the TREML-1 biomarker as an indication of the condition of the patient, alone or in combination with further sepsis markers. | 03-10-2011 |
20100311114 | PREPARATION OF SAMPLES FOR PROTEOME ANALYSIS - The invention mainly concerns methods and systems for the preparation of biological samples for proteome analysis, N-terminal or C-terminal peptides of proteins are enriched using exopeptidase. | 12-09-2010 |
20100304991 | METHOD OF SELECTING APTAMERS - The present invention is a method for the identification of one or more aptamers to at least one target molecule, the method comprising: selecting candidate aptamer sequences that bind to a target molecule, assigning to the bound sequences a measure (fitness function) of each sequence's aptameric potential, allowing evolution of some or all of the sequences to create a new mixture of candidate sequences, and repeating the method with the newly created candidate aptamer pool until the aggregate aptameric potential of the candidate pool reaches a plateau, wherein sequences present in the final pool are optimal aptamers to the target molecule. | 12-02-2010 |
20100298152 | USE OF APTAMERS IN PROTEOMICS - The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated. | 11-25-2010 |
20100222276 | PROTEASE-SENSITIVE SITE IN APOLIPOPROTEIN A1, THERAPEUTIC AND DIAGNOSTIC IMPLICATIONS - The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport. | 09-02-2010 |
20100212030 | USE OF N-TERMINAL AND C-TERMINAL PROTEOMICS TECHNOLOGY TO ENHANCE PROTEIN THERAPEUTICS AND DIAGNOSTICS - The present invention provides a novel method for stabilizing proteins, by first identifying the proteolytic sites using N- or C-terminal technology, followed by modification of said sites in order to create stabilized proteins, no longer subject to proteolytic cleavage. the method of the invention immediately provides the user with the exact amino acid position of the proteolytic cleavage site in the protein(s) of interest, even in a complex protein sample. This makes the specific modification of such a site much easier and increases the expectation of success as compared to the amount of effort needed, even in a complex protein sample. | 08-19-2010 |